• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Autoimmune Diseases

Roche
Pharma

Roche’s Gazyva wins first FDA nod for membranous nephropathy

Besides lupus nephritis, idiopathic nephrotic syndrome and membranous nephropathy, Gazyva also awaits an FDA decision in systemic lupus erythematosus.
Angus Liu Nov 16, 2026 11:00am
Stamp with blue ink that says FDA Approved

Cosette lands FDA approval for Evoxac liquid in Sjögren’s

Oct 20, 2026 11:22am
High magnification micrograph of diffuse proliferative lupus nephritis

Novartis presses pause on Fabhalta lupus nephritis trial

Oct 19, 2026 10:13am
NVS

Novartis' BTK drug clears ph. 3 in MS sans liver safety signal

Sep 1, 2026 11:10am
Argenx

Argenx preps next potential Vyvgart nod after ph. 3 win

Aug 17, 2026 10:52am
Tavneos

EU regulators offer post-mortem of Tavneos withdrawal decision

Aug 14, 2026 11:04am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings